Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Bellerophon Therapeutics Inc (BLPH) USD0.01

Sell:$4.42 Buy:$4.80 Change: $0.01 (0.22%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.

Contact details

184 Liberty Corner Rd Ste 302
United States
+1 (908) 5744770

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$42.40 million
Shares in issue:
9.51 million
Health Care Equipment
United States
US dollar

Key personnel

  • Jonathan Peacock
    Chairman of the Board
  • Fabian Tenenbaum
    Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
  • Assaf Korner
    Chief Financial Officer, Secretary
  • Parag Shah
    Vice President - Business Operations
  • Martin Dekker
    Vice President - Engineering and Manufacturing
  • Amy Edmonds
    Vice President - Clinical Operations and Administration
  • Wassim Fares
    Chief Medical Officer.
  • Peter Fernandes
    Chief Regulatory and Safety Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.